{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:21:28Z","timestamp":1789042888587,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16182-0","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:55:09Z","timestamp":1782395709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics, safety, and efficacy of fuzuloparib in combination with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer: a phase 1 dose escalation and expansion study"],"prefix":"10.1186","volume":"26","author":[{"given":"Tao","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhou","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifa","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinshuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaohong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"16182_CR1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5534\/wjmh.180040","volume":"37","author":"K Fujita","year":"2019","unstructured":"Fujita K, Nonomura N. Role of Androgen Receptor in Prostate Cancer: A Review. World J Mens Health. 2019;37:288\u201395.","journal-title":"World J Mens Health"},{"key":"16182_CR2","doi-asserted-by":"publisher","unstructured":"Dai C, Heemers H, Sharifi N. Androgen Signaling in Prostate Cancer. Cold Spring Harb Perspect Med. 2017;7(9):a030452. https:\/\/doi.org\/10.1101\/cshperspect.a030452.","DOI":"10.1101\/cshperspect.a030452"},{"key":"16182_CR3","first-page":"243","volume":"15","author":"S Ferretti","year":"2023","unstructured":"Ferretti S, Mercinelli C, Marandino L, et al. Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs. Res Rep Urol. 2023;15:243\u201359.","journal-title":"Res Rep Urol"},{"key":"16182_CR4","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s11864-024-01215-2","volume":"25","author":"T Kulasegaran","year":"2024","unstructured":"Kulasegaran T, Oliveira N. Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management. Curr Treat Options Oncol. 2024;25:914\u201331.","journal-title":"Curr Treat Options Oncol"},{"key":"16182_CR5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373:737\u201346.","journal-title":"N Engl J Med"},{"key":"16182_CR6","doi-asserted-by":"publisher","first-page":"6211059","DOI":"10.1155\/2022\/6211059","volume":"2022","author":"X Wu","year":"2022","unstructured":"Wu X, Han H, Zhang C, et al. The Overall Survival and Safety of Men with Metastatic Hormone-Sensitive Prostate Cancer Treated with Combination Therapy of Novel Androgen Receptor Antagonists and Androgen-Deprivation Therapy: A Systematic Review and Meta-Analysis. J Oncol. 2022;2022:6211059.","journal-title":"J Oncol"},{"key":"16182_CR7","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1038\/onc.2013.206","volume":"32","author":"T Karantanos","year":"2013","unstructured":"Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32:5501\u201311.","journal-title":"Oncogene"},{"key":"16182_CR8","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41420-025-02774-5","volume":"11","author":"F Firdaus","year":"2025","unstructured":"Firdaus F, Napoles OC, Dulce RA, et al. Targeting endoplasmic reticulum stress and nitroso-redox imbalance in neuroendocrine prostate cancer: the therapeutic role of nitric oxide. Cell Death Discov. 2025;11:502.","journal-title":"Cell Death Discov"},{"key":"16182_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12967-025-07529-5","volume":"24","author":"P Hui","year":"2025","unstructured":"Hui P, Lai Y, Fan H, et al. Targeting CHD1L suppresses prostate cancer progression via the FOXO3-PUMA axis. J Transl Med. 2025;24:41.","journal-title":"J Transl Med"},{"key":"16182_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41420-025-02792-3","volume":"11","author":"F Rantanen","year":"2025","unstructured":"Rantanen F, Murum\u00e4gi A, Arjama M, et al. Molecular profiling of ex vivo prostate cancer CAF models captures stromal heterogeneity and drug vulnerabilities. Cell Death Discov. 2025;11:507.","journal-title":"Cell Death Discov"},{"key":"16182_CR11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1186\/s12967-025-07234-3","volume":"23","author":"Q Su","year":"2025","unstructured":"Su Q, Li Z, Zhang N, et al. Mechanistic insights into SLAMF8-mediated prostate cancer metastasis via the TLR4-NF-\u03baB pathway. J Transl Med. 2025;23:1189.","journal-title":"J Transl Med"},{"key":"16182_CR12","doi-asserted-by":"publisher","first-page":"101689","DOI":"10.1016\/j.gendis.2025.101689","volume":"12","author":"H Wang","year":"2025","unstructured":"Wang H, Liang S, Du X, et al. RAB26 promotes prostate cancer progression via the MAPK\/ERK-TWIST1 signaling axis. Genes Dis. 2025;12:101689.","journal-title":"Genes Dis"},{"key":"16182_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41420-025-02904-z","volume":"12","author":"Y Mao","year":"2025","unstructured":"Mao Y, Leng Q, Wu J, et al. CircPPFIA2 drives prostate cancer progression and enzalutamide resistance by sponging miR-646 and miR-1200 to upregulate ETS1. Cell Death Discov. 2025;12:45.","journal-title":"Cell Death Discov"},{"key":"16182_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, Bono JS, et al. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med. 2013;368:138\u201348.","journal-title":"N Engl J Med"},{"key":"16182_CR15","doi-asserted-by":"publisher","first-page":"175883592096872","DOI":"10.1177\/1758835920968725","volume":"12","author":"G Procopio","year":"2020","unstructured":"Procopio G, Chiuri VE, Giordano M, et al. Effectiveness of abiraterone acetate plus prednisone in chemotherapy-na\u00efve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study. Ther Adv Med Oncol. 2020;12:1758835920968725.","journal-title":"Ther Adv Med Oncol"},{"key":"16182_CR16","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983\u201392.","journal-title":"Lancet Oncol"},{"key":"16182_CR17","unstructured":"U.S. Food and Drug Administration: ZYTIGA (abiraterone acetate) Tablets Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202379lbl.pdf"},{"key":"16182_CR18","doi-asserted-by":"publisher","first-page":"564601","DOI":"10.3389\/fcell.2020.564601","volume":"8","author":"M Rose","year":"2020","unstructured":"Rose M, Burgess JT, O\u2019Byrne K, et al. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Front Cell Dev Biol. 2020;8:564601.","journal-title":"Front Cell Dev Biol"},{"key":"16182_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","volume":"24","author":"J Morales","year":"2014","unstructured":"Morales J, Li L, Fattah FJ, et al. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr. 2014;24:15\u201328.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"16182_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41392-024-01893-2","volume":"9","author":"M Kolesnichenko","year":"2024","unstructured":"Kolesnichenko M, Scheidereit C. Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts. Signal Transduct Target Therapy. 2024;9:179.","journal-title":"Signal Transduct Target Therapy"},{"key":"16182_CR21","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017;355:1152\u20138.","journal-title":"Science"},{"key":"16182_CR22","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.3390\/cancers15112885","volume":"15","author":"C Sorrentino","year":"2023","unstructured":"Sorrentino C, Di Carlo E. Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges. Cancers. 2023;15:2885.","journal-title":"Cancers"},{"key":"16182_CR23","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.18632\/oncotarget.28015","volume":"12","author":"RJ Scott","year":"2021","unstructured":"Scott RJ, Mehta A, Macedo GS, et al. Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions. Oncotarget. 2021;12:1600\u201314.","journal-title":"Oncotarget"},{"key":"16182_CR24","doi-asserted-by":"publisher","first-page":"14573","DOI":"10.1073\/pnas.1908547116","volume":"116","author":"B Gui","year":"2019","unstructured":"Gui B, Gui F, Takai T, et al. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. Proc Natl Acad Sci U S A. 2019;116:14573\u201382.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"16182_CR25","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s40265-024-02071-y","volume":"84","author":"L Kostos","year":"2024","unstructured":"Kostos L, Tran B, Azad AA. Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer. Drugs. 2024;84:1093\u2013109.","journal-title":"Drugs"},{"key":"16182_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/978-1-0716-2891-1_19","volume":"2609","author":"P Makhov","year":"2023","unstructured":"Makhov P, Fazliyeva R, Tufano A, et al. Examining the Effect of PARP-1 Inhibitors on Transcriptional Activity of Androgen Receptor in Prostate Cancer Cells. Methods Mol Biol. 2023;2609:329\u201335.","journal-title":"Methods Mol Biol"},{"key":"16182_CR27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.21147\/j.issn.1000-9604.2020.03.08","volume":"32","author":"H Li","year":"2020","unstructured":"Li H, Liu R, Shao B, et al. Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. Chin J Cancer Res. 2020;32:370\u201382.","journal-title":"Chin J Cancer Res"},{"key":"16182_CR28","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005.","journal-title":"N Engl J Med"},{"key":"16182_CR29","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40265-021-01541-x","volume":"81","author":"A Lee","year":"2021","unstructured":"Lee A. Fuzuloparib: First Approval. Drugs. 2021;81:1221\u20136.","journal-title":"Drugs"},{"key":"16182_CR30","doi-asserted-by":"publisher","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","volume":"1","author":"NW Clarke","year":"2022","unstructured":"Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evid. 2022;1:EVIDoa2200043.","journal-title":"NEJM Evid"},{"key":"16182_CR31","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","volume":"41","author":"KN Chi","year":"2023","unstructured":"Chi KN, Rathkopf D, Smith MR, et al. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023;41:3339\u201351.","journal-title":"J Clin Oncol"},{"key":"16182_CR32","doi-asserted-by":"crossref","unstructured":"Chi KN, Sandhu S, Smith MR, et al: Niraparib plus abiraterone acetate with prednisone in patients with\u00a0metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the\u00a0randomized phase III MAGNITUDE trial\u2009. Ann Oncol. 2023;34:772\u2013782.","DOI":"10.1016\/j.annonc.2023.06.009"},{"key":"16182_CR33","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal N, Azad AA, Carles J, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402:291\u2013303.","journal-title":"Lancet"},{"key":"16182_CR34","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","volume":"19","author":"N Clarke","year":"2018","unstructured":"Clarke N, Wiechno P, Alekseev B, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018;19:975\u201386.","journal-title":"Lancet Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16182-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16182-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16182-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:02:14Z","timestamp":1789041734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16182-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16182"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16182-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol and all amendments were approved by the Medical Ethics Committee of Hunan Cancer Hospital and the ethics committees of each participating site. The study was conducted according to the Declaration of Helsinki, Guidelines for Good Clinical Practice, and local laws and regulations. All participants provided written informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xianfeng Zhou, Dapeng Zhang, and Chun Yang are employees of Jiangsu Hengrui Pharmaceuticals. The other authors declare no conflict of interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1079"}}